Exploring Perceived Barriers and Facilitators for Implementing Acute Pain Clinical Trials: A Mixed-Methods Analysis of Ketamine Infusions for Sickle Cell Pain.
Journal of Pain Research 2025 Martha O Kenney, Alexander T Limkakeng, Timothy N Ochoa et al. 1 citation
Vaso-occlusive events (VOEs) are the primary cause of acute pain in individuals with sickle cell disease (SCD), where high-dose opioids are the current standard treatment. Ketamine, a non-opioid analgesic, holds potential for managing acute SCD due to its opioid-sparing properties. This study aimed to explore the barriers and facilitators to an inpatient clinical trial of ketamine infusion for...